NCT04374305View on ClinicalTrials.gov

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 20, 2020

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2030

Conditions
Neurofibromatosis Type 2Vestibular SchwannomaNon-vestibular SchwannomaMeningiomaEpendymoma
Interventions
DRUG

Brigatinib

Oral daily per predetermined dosage per protocol.

DRUG

Neratinib

Oral daily per predetermined dosage per protocol.

Trial Locations (6)

10016

New York University Langone Medical Center, New York

21287

Johns Hopkins Hospital, Baltimore

33136

University of Miami, Miami

55905

Mayo Clinic Hospital - Rochester, Rochester

90095

UCLA Medical Center, Los Angeles

02115

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

collaborator

The Children's Tumor Foundation

OTHER

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Scott R. Plotkin, MD, PhD

OTHER

NCT04374305 - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | Biotech Hunter | Biotech Hunter